Merck Finds Licensing More Palatable Than Large Acquisitions
This article was originally published in The Pink Sheet Daily
During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.
You may also be interested in...
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.